Camurus AB (OSTO:CAMX) Asset Impairment Charge : kr0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Camurus AB Asset Impairment Charge?

Camurus AB's Asset Impairment Charge for the three months ended in Mar. 2024 was kr0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was kr0 Mil.

Camurus AB Asset Impairment Charge Historical Data

The historical data trend for Camurus AB's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Asset Impairment Charge Chart

Camurus AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Camurus AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Camurus AB Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

Camurus AB Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Camurus AB's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Camurus AB (OSTO:CAMX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OSTO:CAMX) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

7CA:Germany

Address

Ideon Science Park, Lund, SWE, SE-223 70

Website

https://www.camurus.com

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.